Download PDF
CC BY-NC-ND 4.0 · Arch Plast Surg 2022; 49(03): 310-314
DOI: 10.1055/s-0042-1748643
Cosmetic
Case Report

Midface Infection after COVID-19 Vaccination in a Patient with Calcium Hydroxylapatite Dermal Filler: A Case Report and Literature Review

Hong Bae Jeon
1   Department of Plastic and Reconstructive Surgery, Dankook University Hospital, Cheonan, Chungnam, Republic of Korea
,
Jae Hee Yoon
1   Department of Plastic and Reconstructive Surgery, Dankook University Hospital, Cheonan, Chungnam, Republic of Korea
,
Nam Kyu Lim
1   Department of Plastic and Reconstructive Surgery, Dankook University Hospital, Cheonan, Chungnam, Republic of Korea
2   Department of Plastic and Reconstructive Surgery, Dankook University College of Medicine, Cheonan, Chungnam, Republic of Korea
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

The emergence of vaccines for coronavirus disease 2019 (COVID-19) raises risk of possible adverse events from interaction between the vaccines and facial aesthetic care. A 47-year-old female with no medical comorbidities visited our emergency room due to midface painful swelling after 3 hours following receiving the second dose of the messenger RNA BNT162b2 COVID-19 vaccine. About 14 years ago, she underwent nonsurgical augmentation on the nasojugal groove with a calcium hydroxylapatite dermal filler. We performed incision and drainage under general anesthesia on the next day. During operation, yellowish pus-like materials bulged out. After an operation, we performed a combination therapy with antibiotics and methylprednisolone. Her symptoms improved day by day after surgery, and then a complete recovery was achieved at 3 weeks after the treatment. In conclusion, providers of aesthetic procedures are to be aware of the potential risks of such vaccines for patients who already had or seek to receive dermal filler injections.

Keywords

COVID-19 vaccine - dermal filler - inflammation

Author Contributions

Conceptualization: N.K.L. Data curation: H.B.J., J.H.Y., and N.K.L. Formal analysis: N.K.L. Methodology: N.K.L. Project administration: N.K.L. Visualization: J.H.Y. and N.K.L. Writing-original draft: H.B.J., J.H.Y., and N.K.L. Writing-review and editing: H.B.J. and N.K.L.


Ethical Approval

This study was approved by the Institutional Review Board (IRB No. 2021–10–017).


Patient Consent

The patient provided written informed consent for the publication and the use of her images.




Publication History

Article published online:
27 May 2022

© 2022. The Korean Society of Plastic and Reconstructive Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Nayak LM. Commentary on “Coronavirus Vaccine Considerations for the Aesthetic Patient” by Rice et al.-Our Duty to Our Patients. Facial Plast Surg Aesthet Med 2021; 23 (02) 76-77
    CrossrefPubMedGoogle Scholar
  • 2 Gotkin RH, Gout U, Sattler S. et al. Global recommendations on COVID-19 vaccines and soft tissue filler reactions: a survey-based investigation in cooperation with the International Society for Dermatologic and Aesthetic Surgery (ISDS). J Drugs Dermatol 2021; 20 (04) 374-378
    CrossrefPubMedGoogle Scholar
  • 3 Michon A. Hyaluronic acid soft tissue filler delayed inflammatory reaction following COVID-19 vaccination - a case report. J Cosmet Dermatol 2021; 20 (09) 2684-2690
    CrossrefPubMedGoogle Scholar
  • 4 Rowland-Warmann MJ. Hypersensitivity reaction to hyaluronic acid dermal filler following novel coronavirus infection - a case report. J Cosmet Dermatol 2021; 20 (05) 1557-1562
    CrossrefPubMedGoogle Scholar
  • 5 Munavalli GG, Guthridge R, Knutsen-Larson S, Brodsky A, Matthew E, Landau M. “COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment”. Arch Dermatol Res 2022; 314 (01) 1-15
    CrossrefPubMedGoogle Scholar
  • 6 Ghasemi S, Dashti M. Fight against COVID-19 with mRNA vaccines and interaction with dermal fillers. Clin Exp Vaccine Res 2021; 10 (02) 151-153
    CrossrefPubMedGoogle Scholar
  • 7 Pau M, Reinbacher KE, Feichtinger M, Navysany K, Kärcher H. The mandibular symphysis as a starting point for the occlusal-level reconstruction of panfacial fractures with bicondylar fractures and interruption of the maxillary and mandibular arches: report of two cases. J Craniomaxillofac Surg 2014; 42 (04) e51-e56
    CrossrefPubMedGoogle Scholar
  • 8 Owczarczyk-Saczonek A, Zdanowska N, Wygonowska E, Placek W. The Immunogenicity of hyaluronic fillers and its consequences. Clin Cosmet Investig Dermatol 2021; 14: 921-934
    CrossrefPubMedGoogle Scholar
  • 9 Jansen DA, Graivier MH. Evaluation of a calcium hydroxylapatite-based implant (Radiesse) for facial soft-tissue augmentation. Plast Reconstr Surg 2006; 118 (3, Suppl): 22S-30S
    CrossrefPubMedGoogle Scholar
  • 10 Munavalli GG, Knutsen-Larson S, Lupo MP, Geronemus RG. Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation. JAAD Case Rep 2021; 10: 63-68
    CrossrefPubMedGoogle Scholar